Protalix BioTherapeutics (PLX) Times Interest Earned (2011 - 2025)
Protalix BioTherapeutics (PLX) posted quarterly Times Interest Earned of $3.48 for Q4 2025, down 75.32% year-over-year from $14.11 in Q4 2024, and down 25.34% quarter-over-quarter from $4.66 in Q3 2025.
Protalix BioTherapeutics (PLX) Times Interest Earned (2011 - 2025) Analysis & Trends
Protalix BioTherapeutics' Times Interest Earned history runs 15 years deep, the most recent figure standing at $3.48 for Q4 2025.
- In Q4 2025, Times Interest Earned fell 75.32% year-over-year to $3.48; the TTM figure through Mar 2026 stood at -$22.46 (down 735.39% YoY), while the FY2025 annual figure was -$0.11, down 241.25% from the prior year.
- Times Interest Earned for Q4 2025 stood at $3.48, down from $4.66 in the prior quarter.
- The five-year high for Times Interest Earned was $5615.0 in Q4 2023, with the low at -$690.83 in Q1 2025.
- The 5-year median for Times Interest Earned is -$2.0 (2023), against an average of $273.57.
- The sharpest annual moves came in 2024 and 2025: Times Interest Earned jumped 335.57% in 2024, then plunged 10797.41% in 2025.
- Protalix BioTherapeutics' Times Interest Earned stood at -$6.28 in 2021, then gained by 22.18% to -$4.89 in 2022, then soared by 114915.52% to $5615.0 in 2023, then slumped by 99.75% to $14.11 in 2024, then slumped by 75.32% to $3.48 in 2025.
- Business Quant data shows PLX's Times Interest Earned at $3.48 in Q4 2025, $4.66 in Q3 2025, and -$690.83 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.48 |
| Sep 30, 2025 | 4.66 |
| Mar 31, 2025 | -690.83 |
| Dec 31, 2024 | 14.11 |
| Sep 30, 2024 | 9.66 |
| Jun 30, 2024 | -6.40 |
| Mar 31, 2024 | -6.34 |
| Dec 31, 2023 | 5,615.00 |
| Sep 30, 2023 | -4.10 |
| Jun 30, 2023 | 15.65 |
| Mar 31, 2023 | -2.28 |
| Sep 30, 2022 | -4.89 |
| Jun 30, 2022 | -8.87 |
| Mar 31, 2022 | -1.67 |
| Dec 31, 2021 | -6.28 |
| Sep 30, 2021 | -0.78 |
| Jun 30, 2021 | -4.16 |
| Mar 31, 2021 | -1.72 |
| Dec 31, 2020 | 1.31 |
| Sep 30, 2020 | -1.31 |